Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease

Neurology

Volumn 49, Issue 3, 1997, Pages 724-728

  Shannon, Kathleen M ^a   Bennett Jr , J P ^b   Friedman, J H ^c  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; PRAMIPEXOLE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VISUAL HALLUCINATION;

EID: 0030869562     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.724     Document Type: Article

References (26)

1. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993;8:263-270.
2. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-S12.
3. 2 receptor agonist. Eur J Pharmacol 1992;215:161-170.
4. Lieberman A. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Neurology 1992;42(suppl 4):37-40.
5. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S13-S21.
6. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
7. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995; 45(suppl 3): 528-534.
8. 4 receptors. Eur J Pharmacol 1995;290:29-36.
9. Teychenne PF, Bergsrud D, Elton RL, Racy A. Bromocriptine: long-term low-dose therapy in Parkinson's disease. Clin Neuropharmacol 1986;9:138-145.
10. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1994;4(suppl 1):S86-S94.
11. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
13. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987; 153-163.
14. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990; 40:927-933.
15. Alberts MJ, Stajich J, Olanow CW. A randomized blinded study of low-dose bromocriptine versus low-dose carbidopa/ levodopa in untreated Parkinson's patients. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987:201-208.
16. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomized, prospective five year study comparing low-dose bromocriptine with low-dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57: 903-910.
17. Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. Can J Neurol Sci 1987;14:576-580.
18. Rascol A, Guiraud B, Montastruc J, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
19. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, van der Burg W, Lakke JP. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986;36:291-293.
20. Stern G, Lees A. Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease. Adv Neurol 1986;45:525-527.
21. Tolosa E, Blesa R, Bayes A, Forcadell F. Low-dose bromocriptine in the early phases of Parkinson's disease. Clin Neuropharmacol 1987;10:168-174.
22. United Kingdom Bromocriptine Research Group. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry 1989;52:77-82.
23. van der Drift JHA. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study. Adv Neurol 1987;45:529-534.
24. Taylor JR, Lawrence MS, Redmond DE, et al. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991;199:389-391.
25. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
26. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.